Cystic Fibrosis (CF) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Cystic Fibrosis (CF) Emerging Therapy and TPP Insights

Thelansis’s “Cystic Fibrosis (CF) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cystic Fibrosis (CF) Overview

Cystic Fibrosis (CF) is a serious, life-shortening autosomal recessive genetic disorder caused by mutations in the CFTR gene, resulting in a defective chloride and water channel that disrupts fluid transport across epithelial cells. This core defect leads to the formation of abnormally thick, sticky secretions that obstruct and damage multiple organs, most critically the lungs (causing chronic infection, inflammation, and progressive bronchiectasis) and the pancreas (leading to insufficiency and malabsorption). Clinical presentation often begins in infancy with a persistent cough, recurrent pulmonary issues, and poor growth, while an elevated sweat chloride test and genetic analysis typically confirm diagnosis. Treatment has been significantly advanced by CFTR modulators (like elexacaftor/tezacaftor/ivacaftor), which target the underlying protein malfunction in eligible patients, used alongside essential supportive care such as airway clearance, antibiotics, and enzyme replacement therapy, all of which are managed through lifelong, multidisciplinary care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)